Showing results (101-110 of 130) with videos related to

Sort By:
Pageof 13
Future Oncology (London, England)|March 31, 2025
A plain language summary of the results from the MAGNITUDE study assessing how effective and how safe niraparib and abiraterone acetate with prednisone is in patients with metastatic castration-resistant prostate cancerKim N Chi, Dana Rathkopf, Matthew R Smith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 26, 2014
Dose-response relationship in phase i clinical trials: a European Drug Development Network (EDDN) Collaboration StudyVictor Moreno García, David Olmos, Carlos Gomez-Roca, et al.
European Urology|November 6, 2020
Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based TreatmentVicenç Ruiz de Porras, Xieng C Wang, Luis Palomero, et al.
European Urology Oncology|May 18, 2019
Consensus Statement on Circulating Biomarkers for Advanced Prostate CancerSemini Sumanasuriya, Aurelius Omlin, Andrew Armstrong, et al.
The Prostate|September 13, 2021
Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutationsAlexandra O Sokolova, Catherine H Marshall, Rebeca Lozano, et al.
Cancers|June 2, 2021
Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) PatientsRebeca Lozano, David Lorente, Isabel M Aragon, et al.
Journal for Immunotherapy of Cancer|June 28, 2022
Tumor immune microenvironment of primary prostate cancer with and without germline mutations in homologous recombination repair genesAnna Sofia Trigos, Anupama Pasam, Patricia Banks, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2010
Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetateAlison H M Reid, Gerhardt Attard, Daniel C Danila, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2022
Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)Maha Hussain, Claire Corcoran, Caroline Sibilla, et al.
European Journal of Cancer (Oxford, England : 1990)|June 15, 2019
Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancerVincenza Conteduca, Elena Castro, Daniel Wetterskog, et al.
Pageof 13